A股異動 | 華昌化工漲停 參股投資公司研發新冠核酸測試盒
格隆匯2月10日丨華昌化工(002274.SZ)漲停,報6.38元,總市值60.76億元。

華昌化工此前發佈公告稱,根據南京生物醫藥谷官宣,公司參與投資的蘇州瑞華投資合夥企業(公司佔基金份額10%)參股企業——南京世和基因生物技術有限公司,實踐醫學已成功研發出新冠病毒核酸檢測試劑盒,並正在申請進入國家藥監局為此次疫情開闢的應急審批通道。該項創投投資額5000萬元,持股比例0.8785%。公司強調,上述事項,存在一定的不確定性,敬請投資者注意。
同時,華昌化工表示,公司所處的張家港地區,目前尚無疫情病例發生;公司化工產業板塊春節期間滿負荷生產,物流未受限,庫存數量與上年相比無重大變化,產銷平衡;產品價格與前期相比持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.